Our speaker, Dr. Nathan Staff from Mayo Clinic, will share the
phase 2 study on mesenchymal stem cells derived from patient
adipose (fat) tissue as therapy for ALS.
Dr. Staff is a neurologist at Mayo Clinic in Rochester, Minnesota, and an associate professor of neurology at the Mayo Clinic College of Medicine and Science.
His research focus is to discover new treatments or prevent peripheral nervous system damage that occurs after surgery, from chemotherapy and ALS. Dr. Staff's Translational Neuromuscular Disease Research Lab helps accomplish the development of treatments in the laboratory setting and then apply them in clinical trials.
Dr. Staff's research team has led studies focused on mesenchymal stem cells (MSCs) in amyotrophic lateral sclerosis (ALS), having completed a Phase I first-in-human study and launched a Phase II study using these cells. Active clinical trials for the Translational Neuromuscular Disease Research Lab include:
Intrathecal Autologous Adipose-Derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS)
Safety and Efficacy of Repeated Administration of NurOwn in ALS Patients
Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS
Comments
Post a Comment